By Stephen Nakrosis
Shares of Q32 Bio were touching all-time lows in the after-hours market following results from a pair of Phase 2a clinical trials of the company's alopecia treatment bempikibart.
The company said Tuesday that results from its Signal-AA trial demonstrated encouraging clinical activity of bempikibart in patients with alopecia areata, while the results from its Signal-AD trial in atopic dermatitis demonstrated promising findings in Part A but didn't meet primary endpoint in Part B.
After the bell, the company's shares had fallen 66%, to trade at $8.20. The stock touched an all-time low of $8.24 on Nov. 16, 2023.
Jason Campagna, the chief medical officer of Q32 Bio, said the company was looking forward to advancing bempikibart as a potential treatment for alopecia areata, which causes hair loss.
Chief Executive Jodie Morrison said Q32 plans to conduct a review to better understand the results of the Signal-AD trial.
Bempikibart was observed to be safe and well tolerated across both trials, the company said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
December 10, 2024 18:32 ET (23:32 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.